title: High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
abstract: Selection of a suitable formulation that provides adequate product stability is an important aspect of the development of biopharmaceutical products. Stability of proteins includes not only resistance to chemical modifications but also conformational and colloidal stabilities. While chemical degradation of antibodies is relatively easy to detect and control, propensity for conformational changes and/or aggregation during manufacturing or long-term storage is difficult to predict. In many cases, the formulation factors that increase one type of stability may significantly decrease another type under the same or different conditions. Often compromise is necessary to minimize the adverse effects of an antibody formulation by careful optimization of multiple factors responsible for overall stability. In this study, high-throughput stress and characterization techniques were applied to 96 formulations of anti-streptavidin antibodies (an IgG1 and an IgG2) to choose optimal formulations. Stress and analytical methods applied in this study were 96-well plate based using an automated liquid handling system to prepare the different formulations and sample plates. Aggregation and clipping propensity were evaluated by temperature and mechanical stresses. Multivariate regression analysis of high-throughput data was performed to find statistically significant formulation factors that alter measured parameters such as monomer percentage or unfolding temperature. The results of the regression models were used to maximize the stabilities of antibodies under different formulations and to find the optimal formulation space for each molecule. Comparison of the IgG1 and IgG2 data indicated an overall greater stability of the IgG1 molecule under the conditions studied. The described method can easily be applied to both initial preformulation screening and late-stage formulation development of biopharmaceutical products.
authors.affiliation: Process & Product Development, Amgen, Inc., Seattle, WA, USA.
authors.forename: Larysa
authors.initials: L
authors.lastname: Alekseychyk
authors.affiliation: Biostatistics, Amgen, Inc., Seattle, WA, USA.
authors.forename: Cheng
authors.initials: C
authors.lastname: Su
authors.affiliation: Process & Product Development, Amgen, Inc., Seattle, WA, USA.
authors.forename: Gerald W
authors.initials: GW
authors.lastname: Becker
authors.affiliation: Process & Product Development, Amgen, Inc., Seattle, WA, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Treuheit
authors.affiliation: Process & Product Development, Amgen, Inc., Seattle, WA, USA razinkov@amgen.com.
authors.forename: Vladimir I
authors.initials: VI
authors.lastname: Razinkov
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology; D002850:Chromatography, Gel; D055808:Drug Discovery; D057166:High-Throughput Screening Assays / Q000379:methods / Q000592:standards; D006863:Hydrogen-Ion Concentration; D057927:Hydrophobic and Hydrophilic Interactions; D007074:Immunoglobulin G / Q000737:chemistry / Q000276:immunology / Q000302:isolation & purification; D055550:Protein Stability; D019809:Streptavidin / Q000276:immunology; D013696:Temperature
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D019809:Streptavidin
keywords: aggregation propensity; biopharmaceuticals; design of experiment; drug development; formulation screening; high-throughput method; manufacturability; protein characterization